Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP266
MIFTS: 61

Hypoxia

Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hypoxia

About this section

MalaCards integrated aliases for Hypoxia:

Name: Hypoxia 50 69

External Ids:

UMLS 69 C0242184
Sources

Summaries for Hypoxia

About this section
Novus Biologicals : 52 Hypoxia is a pathological condition in which the body as a whole (generalized hypoxia) or region of the body (tissue hypoxia) is deprived of adequate oxygen supply. Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. Hypoxia inducible factor-1 (HIF-1) is a transcription factor that regulates adaptive responses to a lack of oxygen in mammalian cells. HIF-1 consists of two proteins, HIF-1 alpha and HIF-1 beta. HIF-1 alpha accumulates under hypoxic conditions whereas HIF-1 beta is constitutively expressed. HIF-1 alpha is an important mediator of the hypoxic response of tumor cells and controls the up-regulation of a number of factors important for solid tumor expansion including the angiogenic factor VEGF.

MalaCards based summary : Hypoxia is related to acute mountain sickness and renal cell carcinoma, nonpapillary, and has symptoms including physical appearance, body, increased sweating and physical symptom. An important gene associated with Hypoxia is HIF1A (Hypoxia Inducible Factor 1 Alpha Subunit), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Pathways in cancer. The drugs Dopamine and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include endothelial, lung and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

NINDS : 50 Cerebral hypoxia refers to a condition in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow. Drowning, strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide poisoning, and complications of general anesthesia can create conditions that can lead to cerebral hypoxia. Symptoms of mild cerebral hypoxia include inattentiveness, poor judgment, memory loss, and a decrease in motor coordination. Brain cells are extremely sensitive to oxygen deprivation and can begin to die within five minutes after oxygen supply has been cut off. When hypoxia lasts for longer periods of time, it can cause coma, seizures, and even brain death.  In brain death, there is no measurable activity in the brain, although cardiovascular function is preserved. Life support is required for respiration.

Sources

Related Diseases for Hypoxia

About this section

Diseases related to Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 571)
# Related Disease Score Top Affiliating Genes
1 acute mountain sickness 30.7 EGLN1 HIF1A HIF1AN VHL
2 renal cell carcinoma, nonpapillary 30.4 EPAS1 HIF1A HIF1AN MTOR VHL
3 clear cell renal cell carcinoma 30.3 EPAS1 HIF1A VHL
4 polycythemia 30.3 EGLN1 EPAS1 HIF1A VHL
5 fumarate hydratase deficiency 29.8 HIF1A VHL
6 erythrocytosis, familial, 2 29.8 EGLN1 EPAS1 HIF1A VHL
7 primary polycythemia 29.6 EGLN1 EPAS1 VHL
8 retinal hemangioblastoma 29.5 EPAS1 HIF1A VHL
9 kidney cancer 29.5 EPAS1 HIF1A MTOR VHL
10 renal clear cell carcinoma 29.4 HIF1A MTOR VHL
11 cerebral hypoxia 12.4
12 respiratory underresponsiveness to hypoxia and hypercapnia 11.9
13 polycythemia due to hypoxia 11.9
14 anoxia 11.5
15 exudative vitreoretinopathy 1 11.3
16 pulmonary edema 11.1
17 brain ischemia 11.1
18 apnea of prematurity 11.1
19 tempi syndrome 11.1
20 neonatal hypoxic and ischemic brain injury 11.1
21 asphyxia neonatorum 11.1
22 methemoglobinemia due to deficiency of methemoglobin reductase 10.9
23 chronic mountain sickness 10.8
24 exudative vitreoretinopathy 6 10.8
25 pneumothorax, primary spontaneous 10.8
26 congenital laryngeal palsy 10.8
27 hantavirus pulmonary syndrome 10.8
28 methemoglobinemia type iv 10.8
29 leukostasis 10.8
30 exudative vitreoretinopathy 4 10.8
31 exudative vitreoretinopathy 7 10.8
32 exudative vitreoretinopathy 2, x-linked 10.8
33 exudative vitreoretinopathy 5 10.8
34 severe acute respiratory syndrome 10.8
35 endotheliitis 10.7
36 cerebritis 10.6
37 ischemia 10.5
38 autosomal dominant secondary polycythemia 10.5 EGLN1 EPAS1
39 polycystic kidney disease 10.4
40 neuronitis 10.4
41 prostatitis 10.4
42 pancreatitis 10.3
43 lung cancer 10.3
44 hepatocellular carcinoma 10.3
45 squamous cell carcinoma 10.3
46 pancreatic cancer 10.3
47 glioma 10.3
48 glioblastoma 10.2
49 retinitis 10.2
50 prostate cancer 10.2

Graphical network of the top 20 diseases related to Hypoxia:



Diseases related to Hypoxia
Sources

Symptoms & Phenotypes for Hypoxia

About this section

UMLS symptoms related to Hypoxia:


physical appearance, body, increased sweating, physical symptom, hot flushes, skin symptoms, motor symptom, hyperoxia, chills, vertigo, syncope, sneezing, signs and symptoms, respiratory, signs and symptoms, digestive, signs and symptoms, seizures, icterus, hoarseness, hemoptysis, headache, fever, edema, dyspnea, cyanosis, coughing, cheyne-stokes respiration, cachexia, apnea, anoxemia

MGI Mouse Phenotypes related to Hypoxia:

43 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 EGLN1 EGLN2 EGLN3 EP300 EPAS1 HIF1A
2 homeostasis/metabolism MP:0005376 10.38 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
3 cellular MP:0005384 10.36 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
4 growth/size/body region MP:0005378 10.32 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
5 hematopoietic system MP:0005397 10.27 EPAS1 HIF1A MTOR P4HTM RORA VHL
6 embryo MP:0005380 10.26 CITED2 EGLN1 EGLN2 EGLN3 EP300 EPAS1
7 immune system MP:0005387 10.23 RORA TIGAR VHL ARNT CITED2 EGLN1
8 mortality/aging MP:0010768 10.22 ARNT CITED2 EGLN1 EGLN3 EP300 EPAS1
9 craniofacial MP:0005382 10.19 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
10 muscle MP:0005369 10.18 EGLN1 EGLN2 EGLN3 EP300 EPAS1 HIF1A
11 nervous system MP:0003631 10.06 EPAS1 HIF1A HIPK2 HYOU1 MTOR RORA
12 liver/biliary system MP:0005370 10.03 ARNT EGLN1 EGLN2 EGLN3 EPAS1 HIF1A
13 normal MP:0002873 9.86 ARNT CITED2 EGLN3 EP300 HIF1A HIF1AN
14 renal/urinary system MP:0005367 9.81 ARNT CITED2 EGLN1 EP300 HIF1A HIPK2
15 respiratory system MP:0005388 9.61 CITED2 EGLN1 EP300 EPAS1 HIF1A HIF1AN
16 vision/eye MP:0005391 9.23 HIPK2 P4HTM VHL CITED2 EGLN3 EP300
Sources

Drugs & Therapeutics for Hypoxia

About this section

Drugs for Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 616)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Nitric Oxide Approved Phase 4,Phase 3,Phase 1,Phase 2 10102-43-9 145068
3
Levodopa Approved Phase 4 59-92-7 6047
4
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
5
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
6
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2 59467-70-8 4192
7
Metformin Approved Phase 4,Phase 2,Phase 1 657-24-9 4091 14219
8
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
9
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
10
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
11
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 3 51384-51-1, 37350-58-6 4171
12
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
13
Succinylcholine Approved Phase 4 306-40-1 5314
14
Terbutaline Approved Phase 4 23031-25-6 5403
15
Bosentan Approved, Investigational Phase 4,Phase 1 147536-97-8 104865
16
Adenosine Approved, Investigational Phase 4,Phase 1,Phase 2 58-61-7 60961
17
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
18
Angiotensin II Approved, Investigational Phase 4,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
19
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
20
Budesonide Approved Phase 4,Phase 1 51333-22-3 5281004 63006
21
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3 2078-54-8 4943
22
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
23
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 437-38-7 3345
25
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
26
Acetylcysteine Approved, Investigational Phase 4,Early Phase 1 616-91-1 12035
27
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 7487-88-9 24083
28
Bromhexine Approved Phase 4 3572-43-8
29 Racepinephrine Approved Phase 4,Phase 2,Phase 3 329-65-7
30
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
31
Indomethacin Approved, Investigational Phase 4,Phase 1,Phase 2 53-86-1 3715
32
Dipyridamole Approved Phase 4 58-32-2 3108
33
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
34
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
35
Nifedipine Approved Phase 4 21829-25-4 4485
36
Captopril Approved Phase 4 62571-86-2 44093
37
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
38
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
39
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
40
Bisoprolol Approved Phase 4 66722-44-9 2405
41
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
42
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
43
Rocuronium Approved Phase 4,Phase 3 119302-91-9, 143558-00-3 441290
44
Histamine Approved, Investigational Phase 4,Phase 2 51-45-6, 75614-87-8 774
45
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 76631-46-4, 113775-47-6 5311068 56032 68602
46
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
47
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
48
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3 59-66-5 1986
49
Dutasteride Approved, Investigational Phase 4 164656-23-9 6918296 152945
50
Remifentanil Approved Phase 4 132875-61-7 60815

Interventional clinical trials:

(show top 50) (show all 1261)

# Name Status NCT ID Phase Drugs
1 Intermittent Hypoxia 2: Cardiovascular and Metabolism Unknown status NCT02058823 Phase 4 Placebo;Placebo;Valsartan;Amlodipine
2 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
3 Sevoflurane Decreases the Risk of Postoperative Delirium After Cerebral Hypoxemia During Surgery Unknown status NCT02133638 Phase 4 Sevoflurane;Propofol
4 Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Tonsillectomy or Adeno-tonsillectomy in Children Unknown status NCT02205580 Phase 4 continuous intravenous sufentanil 0.02μg•kg－1•h－1 infusion;continuous intravenous sufentanil 0.03μg•kg－1•h－1 infusion;continuous intravenous sufentanil 0.04μg•kg－1•h－1 infusion
5 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
6 Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage Unknown status NCT01180192 Phase 4 oxygen
7 Home Oxygen Therapy in Bronchiolitis Unknown status NCT01216553 Phase 4
8 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Unknown status NCT02346149 Phase 4
9 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
10 CPAP in Liver Transplant Unknown status NCT00510770 Phase 4
11 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
12 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
13 Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation Unknown status NCT01595399 Phase 4 atropine;Placebo
14 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
15 AZ, MZ, and the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
16 Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers Completed NCT01873612 Phase 4
17 Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation Completed NCT01692821 Phase 4 100% oxygen breathing;15% oxygen in N2 breathing;12% oxygen in N2 breathing
18 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females Completed NCT02356107 Phase 4 5-hydroxytryptophan and Creatine monohydrate
19 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy Completed NCT02628106 Phase 4 Lipo-PGE1
20 Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects. Completed NCT00924833 Phase 4 placebo;Carvedilol;Nebivolol
21 Muscle Fatigue and Carbonic Anhydrase Inhibitors Completed NCT02758470 Phase 4 Acetazolamide;Methazolamide
22 Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure Completed NCT00517725 Phase 4 carvedilol;bisoprolol;Nebivolol
23 Ambulatory Oxygen Effects on Muscles in COPD Completed NCT01722370 Phase 4 Oxygen;Medical air equivalent
24 Single High Dose Vitamin C, E in Severe Birth Asphyxia Completed NCT01743742 Phase 4 Vitamin E, Vitamin C
25 Doxapram as an Additive to Propofol Sedation in Sedation for ERCP Completed NCT02171910 Phase 4 Doxapram;Placebo
26 CPAP in SAHS Patients With Hypertension Completed NCT02398032 Phase 4
27 The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy Completed NCT01725464 Phase 4
28 Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate Completed NCT00880672 Phase 4 dutasteride
29 Safety Study of Analgesia After Craniotomy Surgery With End Tidal (ET) Carbon Dioxide (CO2) Monitoring Completed NCT01327677 Phase 4 Fentanyl;Fentanyl
30 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
31 Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation Completed NCT01260662 Phase 4 Propofol;1:1 Propofol/Ketamine;4:1 Propofol/Ketamine
32 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
33 Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress Completed NCT01830335 Phase 4 Indomethacin;Placebo
34 The Use of Statins for Myocardial Death Prevention Completed NCT00772564 Phase 4 Atorvastatin
35 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea Before and After Treatment With CPAP. Completed NCT00360659 Phase 4
36 Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study) Completed NCT01103336 Phase 4 pretreatment with intravenous nicorandil vs. placebo before coronary angiography
37 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude Completed NCT02024386 Phase 4 Riociguat
38 Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition Completed NCT01545479 Phase 4 captopril 25mg
39 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea and Healthy Controls. Completed NCT00291993 Phase 4
40 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4 Lucentis
41 Influence of Cardiopulmonary Bypass, and Sevoflurane or Propofol Anesthesia, on Tissue Oxygen Saturation. Completed NCT02593448 Phase 4
42 To Evaluate the Effect of Chlorhexidine-benzidamine Administration Completed NCT03253497 Phase 4 Chlorobenzene Liquid
43 The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia Completed NCT01091571 Phase 4 Dipyridamole;Placebo
44 The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Completed NCT01507766 Phase 4 early enteral nutrition;Delayed enteral nutrition
45 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4 Erythropoietin
46 Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients Completed NCT01996124 Phase 4 Indacaterol Fumarate;Placebo
47 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
48 Bispectral Index and Clinical Parameters Evaluation in Dental Procedures Completed NCT02671578 Phase 4 Nitrous Oxide
49 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4 Human insulin;Human Insulin
50 Short Term Physiological Effects of Nasal High Flow Oxygen on Respiratory Mechanics Completed NCT02363920 Phase 4

Search NIH Clinical Center for Hypoxia

Sources

Genetic Tests for Hypoxia

About this section
Sources

Anatomical Context for Hypoxia

About this section

MalaCards organs/tissues related to Hypoxia:

38
Endothelial, Lung, Brain, Breast, Prostate, Heart, Kidney
Sources

Publications for Hypoxia

About this section

Articles related to Hypoxia:

(show top 50) (show all 6728)
# Title Authors Year
1
Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma. ( 29450727 )
2018
2
Protein S-glutathionylation induced by hypoxia increases hypoxia-inducible factor-1I+ in human colon cancer cells. ( 29113799 )
2018
3
Hypoxia-Induced Signaling Activation in Neurodegenerative Diseases: Targets for New Therapeutic Strategies. ( 29439330 )
2018
4
Transcriptomic profiling reveals gene expression kinetics in patients with hypoxia and high altitude pulmonary edema. ( 29366758 )
2018
5
LncRNA TUG1 serves an important role in hypoxia-induced myocardial cell injury by regulating the miRa89145a895pa89Binp3 axis. ( 29207102 )
2018
6
ERK1/2 and Akt phosphorylation were essential for MGF E peptide regulating cell morphology and mobility but not proangiogenic capacity of BMSCs under severe hypoxia. ( 29441602 )
2018
7
Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. ( 29423096 )
2018
8
Erythropoietin, a putative neurotransmitter during hypoxia, is produced in RVLM neurons and activates them in neonatal Wistar rats. ( 29443550 )
2018
9
Necrostatin-1 protects C2C12 myotubes from CoCl2-induced hypoxia. ( 29436688 )
2018
10
Role of hypoxia-inducible factor-1 in the development of renal fibrosis in mouse obstructed kidney: Special references to HIF-1 dependent gene expression of profibrogenic molecules. ( 29352658 )
2018
11
Hypoxia-inducible factor-1I+ is a critical transcription factor for IL-10-producing B cells in autoimmune disease. ( 29343683 )
2018
12
Hypoxia-inducible KDM3A addiction in multiple myeloma. ( 29444873 )
2018
13
Differences in muscle performance during fatigue may explain the differences in motoneurone excitability between acute and chronic hypoxia. ( 29436725 )
2018
14
Magnesium sulphate induces preconditioning in preterm rodent models of cerebral hypoxia-ischemia. ( 29355709 )
2018
15
TGF-b1 or Hypoxia Enhance Glucose Metabolism and Lactate Production via HIF1A Signaling in Tendon Cells. ( 29447016 )
2018
16
High Wattage E-cigarettes Induce Tissue Hypoxia and Lower Airway Injury: A Randomized Trial. ( 29451806 )
2018
17
Intermittent hypoxia promotes melanoma lung metastasis via oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea. ( 29433520 )
2018
18
Enhancing proliferation and optimizing the culture condition for human bone marrow stromal cells using hypoxia and fibroblast growth factor-2. ( 29448134 )
2018
19
Neuronalinjury and roles of apoptosis and autophagy in a neonatal rat model of hypoxia-ischemia-induced periventricular leukomalacia. ( 29436652 )
2018
20
Hypoxia-induced activation of Twist/miR-214/E-cadherin axis promotes renal tubular epithelial cell mesenchymal transition and renal fibrosis. ( 29277613 )
2018
21
Atrial Arrhythmias and Autonomic Dysfunction in Rats Exposed to Chronic Intermittent Hypoxia. ( 29424572 )
2018
22
Chronic intermittent hypoxia promotes myocardial ischemia-related ventricular arrhythmias and sudden cardiac death. ( 29445096 )
2018
23
NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression. ( 28436035 )
2018
24
Brain changes due to hypoxia during light anaesthesia can be prevented by deepening anaesthesia; a study in rats. ( 29451906 )
2018
25
FAT10 attenuates hypoxia-induced cardiomyocyte apoptosis by stabilizing caveolin-3. ( 29438664 )
2018
26
Mesenchymal stem cells protect against hypoxia-ischemia brain damage by enhancing autophagy through BDNF/mTOR signaling pathway. ( 29451335 )
2018
27
Targeting tumour hypoxia: shifting focus from oxygen supply to demand. ( 29436847 )
2018
28
Glucose & oxygen exhausting liposomes for combined cancer starvation and hypoxia-activated therapy. ( 29438880 )
2018
29
The role of the ATPase inhibitor factor 1 (IF<sub>1</sub>) in cancer cells adaptation to hypoxia and anoxia. ( 29097244 )
2018
30
Intermittent hypoxia, cardiovascular disease and obstructive sleep apnoea. ( 29445526 )
2018
31
Silencing of NADPH oxidase 4 attenuates hypoxia resistance in neuroblastoma cells SHSY-5Y by inhibiting PI3K/Akt-dependent glycolysis. ( 29426376 )
2018
32
Rutaecarpine suppresses proliferation and promotes apoptosis of HPASMCs in hypoxia possibly via HIF-1I+-dependent pathways. ( 29438215 )
2018
33
Chronic intermittent hypoxia and renovascular hypertension: A case of one plus one equals one-half! ( 29377392 )
2018
34
Correction for Ferrari et al., Hypoxia treatment reverses neurodegenerative disease in a mouse model of Leigh syndrome. ( 29382743 )
2018
35
Retinoic acid receptor-related orphan receptor RORI+ regulates differentiation and survival of keratinocytes during hypoxia. ( 28332183 )
2018
36
The relationship between plasma vascular endothelial growth factor and erythrocyte 2,3-bisphosphoglycerate: The putative role of chronic hypoxia. ( 29447940 )
2018
37
Hypoxia Promotes Ectopic Adhesion Ability of Endometrial Stromal Cells via TGF-I^1/Smad Signalling in Endometriosis. ( 29438550 )
2018
38
Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma. ( 28088075 )
2017
39
Persistent generalized periodic discharges: A specific marker of fatal outcome in cerebral hypoxia. ( 27894023 )
2017
40
Long noncoding RNA HAS2-AS1 mediates hypoxia-induced invasiveness of oral squamous cell carcinoma. ( 28485478 )
2017
41
Knockdown of long noncoding antisense RNA brain-derived neurotrophic factor attenuates hypoxia/reoxygenation-induced nerve cell apoptosis through the BDNF-TrkB-PI3K/Akt signaling pathway. ( 28777258 )
2017
42
Role of transglutaminase 2 in PAC1 receptor mediated protection against hypoxia-induced cell death and neurite outgrowth in differentiating N2a neuroblastoma cells. ( 28065858 )
2017
43
Thyroid hormone regulates fibronectin expression through the activation of the hypoxia inducible factor 1. ( 28974422 )
2017
44
Hypoxia treatment reverses neurodegenerative disease in a mouse model of Leigh syndrome. ( 28483998 )
2017
45
A simple method to induce hypoxia-induced vascular endothelial growth factor-A (VEGF-A) expression in T24 human bladder cancer cells. ( 27752923 )
2017
46
Novel lnc RNA regulated by HIF-1 inhibits apoptotic cell death in the renal tubular epithelial cells under hypoxia. ( 28420760 )
2017
47
Chronic Intermittent Hypoxia Differentially Impacts Different States of Inspiratory Activity at the Level of the preBAPtzinger Complex. ( 28936176 )
2017
48
Monomethyltransferase SETD8 regulates breast cancer metabolism via stabilizing hypoxia-inducible factor 1I+. ( 28089831 )
2017
49
Notch1 signaling induces epithelial-mesenchymal transition in lens epithelium cells during hypoxia. ( 28764685 )
2017
50
Loss of smooth muscle cell hypoxia inducible factor-1I+ underlies increased vascular contractility in pulmonary hypertension. ( 27811062 )
2017
Sources

Variations for Hypoxia

About this section
Sources

Expression for Hypoxia

About this section
Search GEO for disease gene expression data for Hypoxia.
Sources

Pathways for Hypoxia

About this section

Pathways related to Hypoxia according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Cellular Senescence (REACTOME) 62
Show member pathways
 12.95 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2
Pathways in cancer 36
12.85 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
3
ErbB signaling pathway 36 1
Show member pathways
 12.47 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
4
Translational Control 4
12.28 ARNT EGLN1 EPAS1 HIF1A HIF1AN HIPK2
5
p53 Signaling 60
Show member pathways
 12.13 EP300 HIF1A HIPK2 PSMA7
6
BMAL1-CLOCK,NPAS2 activates circadian gene expression 62
Show member pathways
 12.1 EP300 HIF1A HIPK2 RORA
7
HIF-1 signaling pathway 36
11.92 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
8
Thyroid hormone signaling pathway 36
11.84 EP300 HIF1A MTOR
9
Angiogenesis (CST) 4
11.84 ARNT EGLN1 EP300 HIF1A HIF1AN
10
Signaling events mediated by VEGFR1 and VEGFR2 1
Show member pathways
 11.79 ARNT EPAS1 HIF1A VHL
11
HIF-1-alpha transcription factor network 1
11.72 ARNT CITED2 EGLN1 EGLN3 EP300 HIF1A
12
Transcription Ligand-dependent activation of the ESR1/SP pathway 21
Show member pathways
 11.61 ARNT EP300 HIF1A
13
Central carbon metabolism in cancer 36
11.56 HIF1A MTOR TIGAR
14
Notch-mediated HES/HEY network 1
11.39 ARNT EP300 HIF1A
15
Photodynamic therapy-induced HIF-1 survival signaling 1
11.38 ARNT EGLN1 HIF1A HIF1AN
16
HIF Repressor Pathways 61
Show member pathways
 11.36 ARNT CITED2 EGLN3 EP300 EPAS1 HIF1A
17
HIF1Alpha Pathway 60
11.29 ARNT EGLN1 EGLN2 EP300 HIF1A HIF1AN
18
Hypoxic and oxygen homeostasis regulation of HIF-1-alpha 1
10.98 ARNT HIF1A HIF1AN HIF3A VHL
19
Amplification and Expansion of Oncogenic Pathways as Metastatic Traits 1
10.82 EPAS1 VHL
20
HIF-2-alpha transcription factor network 1
10.81 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
21
miR-148a/miR-31/FIH1/HIF1andalpha;-Notch signaling in glioblastoma 1
10.53 HIF1A HIF1AN
Sources

GO Terms for Hypoxia

About this section

Cellular components related to Hypoxia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.86 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2 transcription factor complex GO:0005667 9.56 ARNT EP300 EPAS1 HIF1A
3 nucleoplasm GO:0005654 9.53 ARNT CITED2 EGLN2 EGLN3 EP300 EPAS1
4 RNA polymerase II transcription factor complex GO:0090575 9.33 ARNT HIF1A HIPK2

Biological processes related to Hypoxia according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 transcription by RNA polymerase II GO:0006366 9.99 CITED2 EP300 EPAS1 HIF1A HIF3A HIPK2
2 post-translational protein modification GO:0043687 9.92 EPAS1 HIF1A HIF3A PSMA7 VHL
3 angiogenesis GO:0001525 9.89 EPAS1 HIF1A HIF3A RORA
4 positive regulation of endothelial cell proliferation GO:0001938 9.75 ARNT HIF1A MTOR
5 cellular response to hypoxia GO:0071456 9.7 EPAS1 HIF1A HIPK2 HYOU1 MTOR RORA
6 positive regulation of vascular endothelial growth factor production GO:0010575 9.65 ARNT HIF1A RORA
7 positive regulation of glycolytic process GO:0045821 9.63 ARNT HIF1A
8 mRNA transcription by RNA polymerase II GO:0042789 9.62 ARNT HIF1A
9 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.62 ARNT HIF1A
10 response to hypoxia GO:0001666 9.61 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
11 embryonic camera-type eye morphogenesis GO:0048596 9.6 CITED2 HIPK2
12 iris morphogenesis GO:0061072 9.58 HIF1A HIPK2
13 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.58 ARNT EPAS1 HIF1A
14 oxygen homeostasis GO:0032364 9.56 EGLN1 HIF1A
15 embryonic placenta development GO:0001892 9.56 ARNT CITED2 EPAS1 HIF1A
16 voluntary musculoskeletal movement GO:0050882 9.54 HIPK2 MTOR
17 peptidyl-proline hydroxylation to 4-hydroxy-L-proline GO:0018401 9.54 EGLN1 EGLN2 EGLN3
18 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.5 CITED2 HIF1AN VHL
19 positive regulation of hormone biosynthetic process GO:0046886 9.49 ARNT HIF1A
20 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.4 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
21 transcription, DNA-templated GO:0006351 10.26 ARNT CITED2 EP300 EPAS1 HIF1A HIF1AN
22 regulation of transcription, DNA-templated GO:0006355 10.25 ARNT CITED2 EP300 EPAS1 HIF1A HIF1AN
23 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 ARNT CITED2 EGLN1 EP300 EPAS1 HIF1A
24 oxidation-reduction process GO:0055114 10.04 EGLN1 EGLN2 EGLN3 HIF1AN HIGD1A P4HTM
25 negative regulation of apoptotic process GO:0043066 10 CITED2 HIF1A HIGD1A HYOU1 VHL
26 positive regulation of transcription, DNA-templated GO:0045893 10 ARNT CITED2 EP300 HIF1A HIPK2 RORA

Molecular functions related to Hypoxia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.91 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
2 transcription factor binding GO:0008134 9.85 ARNT EP300 EPAS1 HIF1A RORA VHL
3 protein dimerization activity GO:0046983 9.8 ARNT EPAS1 HIF1A HIF3A
4 iron ion binding GO:0005506 9.72 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.71 EGLN1 EGLN2 EGLN3 P4HTM
6 RNA polymerase II activating transcription factor binding GO:0001102 9.65 CITED2 EP300 HIPK2
7 histone acetyltransferase binding GO:0035035 9.61 CITED2 EPAS1 HIF1A
8 dioxygenase activity GO:0051213 9.55 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
9 oxygen sensor activity GO:0019826 9.46 EGLN2 HIF1AN
10 peptidyl-proline 4-dioxygenase activity GO:0031545 9.43 EGLN1 EGLN2 EGLN3
11 L-ascorbic acid binding GO:0031418 9.26 EGLN1 EGLN2 EGLN3 P4HTM
12 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.02 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
13 DNA binding transcription factor activity GO:0003700 10 ARNT CITED2 EPAS1 HIF1A HIF3A RORA
Sources

Sources for Hypoxia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....